Ocumension Therapeutics

5DG

Company Profile

  • Business description

    Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

  • Contact

    No. 1858 Yinzhongnan Road
    Guoxiang Subdistrict
    Wuzhong District
    SuzhouJiangsu
    CHN

    T: +86 2161493800

    https://www.ocumension.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    489

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,896.3617.900.23%
DAX 4024,472.3777.19-0.31%
Dow JONES (US)44,569.81111.510.25%
FTSE 1008,967.90100.881.14%
HKSE24,028.37136.050.57%
NASDAQ20,522.4588.89-0.43%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,258.274.99-0.08%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers